Sibylla Biotech

✨ A Year in Review: Progress, Innovation, and Milestones ✨ As 2025 approaches, we reflect on the incredible growth, innovation, and perseverance journey across 2024. This year, we made significant progress across our pipeline, platform, corporate structure, and partnerships. Pipeline Advancements 🚀 We achieved in vivo validation of our platform, a key milestone in demonstrating its potential, and are now planning to guide our lead program toward clinical success and validation. We also validated other internal targets, building a pipeline of potential breakthrough therapeutics. Platform Innovations 💻 We deepened mechanistic insights to widen the application extent of our simulation platform. We empowered the discovery platform with powerful and proprietary AI tools. And much more that we will reveal in the future... Strategic Partnerships 🤝 We proudly signed a collaboration agreement with Ono Pharmaceutical, advancing shared objectives. Corporate Growth 🌟 We strengthened our corporate and operational structure to support our ambitious goals, ensuring an up-and-running team to drive innovation and execution and equipping us with the tools and talent necessary for sustainable growth. Looking Ahead 🔭 2024 has been a transformative year for us, marked by meaningful progress across every aspect of our company. As we progress, we remain committed to pushing boundaries, delivering value, and advancing therapies that make a difference. Our Culture Shines Through 💖 Despite change and growth, our culture remains a pillar of our success: people are at the center, and the team makes the company. In the ups and downs of our human journey, we find joy and support in working together, and this is just magic and unique! Last but not least, this year, 2024, we celebrated the arrival of three new lives from our team: Elia, Federico, and Harriet Liliana. They bring joy and hope for the future. We are proud to #foldthefuture to advance science and create a better world for them and the generations to come. 🌍 Together, we wish you Merry Christmas and toast to another year of innovation, collaboration, impact, and joy! 🌟 #YearInReview #WeAreSibylla #Sibylla

🚀 Groundbreaking Research Alert! 🧬 We proudly announce the findings of an exciting interdisciplinary study authored by our co-founders and PPI-FIT technology inventors Emiliano Biasini and Pietro Faccioli, in collaboration with our CTO Giovanni Spagnolli, our other co-founder Graziano Lolli and an incredible team of scientists among which two sibyllians, Laura Copat and Dino Gasparotto, titled: "Mapping Cryptic Phosphorylation Sites in the Human Proteome" 🔬. This work delves into the hidden world of cryptic phosphosites—phosphorylation sites buried within the protein core in its native state. These sites only become accessible during the protein folding process and may play a pivotal role in protein homeostasis, degradation, and even disease. Key Findings: - 1 in 3 proteins contains at least one cryptic phosphosite. - These sites are evolutionarily conserved, suggesting a critical biological function. - Cryptic phosphosites are linked to cancer-related mutations, potentially influencing tumor fitness and onco-suppressor activity. - Phosphorylation of these cryptic residues can destabilize native protein structures, triggering degradation and impacting protein levels.             This study represents a paradigm shift in our understanding of protein regulation and homeostasis. It also reinforces the potential of protein folding intermediates as a novel target space for therapeutic intervention. At Sibylla Biotech, we’ve long believed that protein folding intermediates hold the key to discovering new drugs. This research confirms that evolution may have exploited these transient states for millions of years to regulate protein function. Now, we are leveraging these insights through our Protein Folding Interference Technology to develop groundbreaking therapeutics. Why This Matters: This study opens up a new frontier in understanding how proteins are regulated and how these mechanisms can be harnessed to fight diseases, including cancer. It also validates our approach to drug discovery, positioning Sibylla Biotech at the forefront of innovation in targeting protein folding intermediates. We’re incredibly proud of this achievement and the collaboration between computational, experimental, and theoretical disciplines that made it possible. 💡 Read the full paper here: https://lnkd.in/dMtg-FnW Join us on this journey to revolutionize drug discovery and unravel the mysteries of protein folding! #foldthefuture #sibylla

"It was a valuable experience to participate in the GPCRs-Targeted Drug Discovery Summit! We had the privilege of meeting experts in this fascinating field and exploring new opportunities to expand Sibylla's Protein Folding Interference technology to these exciting and challenging targets!" Serena Bonifati Carmine Varricchio Cassiano Langini At #Sibylla, we believe that innovation comes from the cross-talking and cross-fertilization of competencies. We foster everyday collaboration among our different departments, and we see extraordinary results in doing that. #wearesibylla

Proud of you, Lorenzo Alibrandi! #foldthefuture in many different ways

We're #hiring a new Biology Lab Technician in Milan, Lombardy. Apply today or share this post with your network. #foldthefuture

We're #hiring a new Biology Staff Scientist in Milan, Lombardy. Apply today or share this post with your network. #foldthefuture

👩🔬👨🔬 🧑💻 A multidisciplinary team from Sibylla Biotech will attend the GPCRs-Targeted Drug Discovery Summit this week in London. Scientists and Principal Investigators from our biology, chemistry, and biophysics teams are coming together to connect with industry leaders. We're committed to expanding the target space for our folding interference technology, and we can't wait to share insights, exchange ideas, and explore new opportunities. Reach out to Serena Bonifati, Carmine Varricchio and Cassiano Langini to know more about Sibylla! 💡 Looking forward to incredible discussions and collaborations! #foldthefuture #Sibylla

Amazing industrial location to showcase an amazing company! Lidia Pieri Lorenzo Alibrandi #investival #lsx #tobaccodock #London #Sibylla #foldthefuture

What about a week jumpstart in London City? Next Monday, our CEO Lidia Pieri and our Corporate Development Manager Lorenzo Alibrandi will be at the Tobacco Dock for the LSX Investival Showcase, presenting our breakthrough technology and plans for the future. At the same time, our CTO Giovanni Spagnolli will be at the Francis Crick Institute for the workshop "New Frontiers in Drug Discovery", to widen the network of industry experts supporting the company in this growth phase. At tea time, we'll head back to Milan! Reach out to meet us! #foldthefuture #sibylla

❤️ together we’ll make the difference #foldthefuture #sibylla